Seaport Therapeutics' official press releases or clinical trial registries

Seaport Therapeutics Secures $225M in Oversubscribed Series B Round Led by General Atlantic

Oct 21, 2024, 06:14 AM

Seaport Therapeutics, a company founded by PureTech, has successfully closed a $225 million oversubscribed Series B financing round. The financing round was led by General Atlantic and includes an impressive group of investors. The funds will be used to advance Seaport Therapeutics' efforts in developing better medicines for depression, anxiety, and other neuropsychiatric disorders. This significant investment comes as the company aims to embrace what it describes as the 'golden age of neuroscience.' SeaportTx announced the news.